New combo aims to stall lung cancer progression

NCT ID NCT03775486

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II trial tests whether adding olaparib to durvalumab helps keep stage IV non-small cell lung cancer from growing after initial chemotherapy. About 400 patients whose cancer did not worsen on standard chemo plus durvalumab will receive either the combination or durvalumab alone as maintenance. The main goal is to see how long the cancer stays controlled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab and olaparib
What this could lead to: If it works, this combination could help keep advanced lung cancer from progressing longer than durvalumab alone, offering a new maintenance option.
What could go wrong: This is a Phase II trial, so results are still early. The combination may not improve survival and could cause more side effects than the single drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Research Site

Bonita Springs, Florida, 34135, United States
Research Site

St. Petersburg, Florida, 33705, United States
Research Site

Tallahassee, Florida, 32308-5304, United States
Research Site

West Palm Beach, Florida, 33401, United States
Research Site

Kansas City, Missouri, 64132, United States
Research Site

Bethlehem, Pennsylvania, 18015, United States
Research Site

Chattanooga, Tennessee, 37404, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Houston, Texas, 77090, United States
Research Site

Aalst, 9300, Belgium
Research Site

Leuven, 3000, Belgium
Research Site

Roeselare, 8800, Belgium
Research Site

Budapest, 1088, Hungary
Research Site

Budapest, 1122, Hungary
Research Site

Debrecen, 4032, Hungary
Research Site

Deszk, 6772, Hungary
Research Site

Farkasgyepü, 8582, Hungary
Research Site

Törökbálint, 2045, Hungary
Research Site

Ahmedabad, 380009, India
Research Site

Ahmedabad, 380053, India
Research Site

Jamnagar, 361008, India
Research Site

Kochi, 682026, India
Research Site

Mysuru, 570021, India
Research Site

Nashik, 422004, India
Research Site

Nashik, 422009, India
Research Site

Pune, 411001, India
Research Site

Thiruvananthapuram, 695011, India
Research Site

Chūōku, 104-0045, Japan
Research Site

Kanazawa, 920-8641, Japan
Research Site

Kurume-shi,, 830-0011, Japan
Research Site

Matsuyama, 791-0280, Japan
Research Site

Nagoya, 460-0001, Japan
Research Site

Sendai, 980-0873, Japan
Research Site

Sunto-gun, 411-8777, Japan
Research Site

Ube-shi, 755-0241, Japan
Research Site

Chihuahua City, 31200, Mexico
Research Site

Culiacán, 80230, Mexico
Research Site

San Luis Potosí City, 78250, Mexico
Research Site

Blaricum, 1261, Netherlands
Research Site

Harderwijk, 3844, Netherlands
Research Site

Tilburg, 5022 GC, Netherlands
Research Site

Bialystok, 15-540, Poland
Research Site

Lodz, 90-302, Poland
Research Site

Poznan, 60-693, Poland
Research Site

Prabuty, 82-550, Poland
Research Site

Arkhangelsk, 163045, Russia
Research Site

Chelyabinsk, 454092, Russia
Research Site

Kursk, 305524, Russia
Research Site

Moscow, 115478, Russia
Research Site

Nal'chik, 360000, Russia
Research Site

P. Herzen Moscow Oncology Rese, 125284, Russia
Research Site

Saint Petersburg, 197022, Russia
Research Site

Sochi, 354000, Russia
Research Site

Yaroslavl, 150054, Russia
Research Site

Dongjakgu, 07061, South Korea
Research Site

Goyang-si, 10408, South Korea
Research Site

Seodaemun-gu, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Suweonsi Paldalgu, 16247, South Korea
Research Site

Dnipro, 49102, Ukraine
Research Site

Kharkiv Region, 61024, Ukraine
Research Site

Kirovohrad, 25006, Ukraine
Research Site

Odesa, 65055, Ukraine
Research Site

Uzhhorod, 88000, Ukraine
Research Site

Zaporizhzhia, 69059, Ukraine
Research Site

Dundee, DD1 9SY, United Kingdom
Research Site

Hull, HU6 7RX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.